Chronic Inflammatory Demyelinating Polyneuropathy

>

The NeurologyLive® Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) clinical focus page is a concentrated place for the latest information on the care and management of patients with CIDP. This page includes podcasts, videos and expert interviews, and news about the latest study and clinical trial findings, FDA actions, and clinical guideline updates.

Latest News

Jean-Philippe Plançon, PhD, MSc  (Credit: EPODIN)
European Commission Approves Efgartigimod Subcutaneous Injection for Forms of CIDP

June 24th 2025

Efgartigimod alfa SC is now approved in Europe for patients with chronic inflammatory demyelinating polyneuropathy, following a positive recommendation from the Committee for Medicinal Products for Human Use.

Rajiv Mallick, PhD  (Credit: LinkedIn)
Real-World Study Highlights Reduced Disability Progression of CIDP With Immunoglobulin Therapy

May 21st 2025

David Cornblath, MD  (Credit: ResearchGate)
Efficacy of CIDP Treatments Immunoglobulin 10% and Efgartigimod Compared Through Matching-Adjusted Indirect Analysis

May 19th 2025

FDA Approves Pre-Filled Syringe Administration for FcRn Modulator Efgartigimod
FDA Approves Pre-Filled Syringe Administration for FcRn Modulator Efgartigimod

April 10th 2025

Pete Salzmann, MD, MBA  (Credit: LinkedIn)
Immunovant Reports Positive Phase 3 and Phase 2b Results for Batoclimab in Myasthenia Gravis and CIDP

March 19th 2025

Video Interviews

More News

© 2025 MJH Life Sciences

All rights reserved.